March 17 (Reuters) - CPEX Pharmaceuticals Inc:
* Says although subjects in placebo group spent less time in euglycemia than
subjects in nasulin group, the different was not statistically significant
* Says will not commence its planned phase 2b trial or other nasulin
development initiatives
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about CPEX Pharmaceuticals Inc click here:) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Says although subjects in placebo group spent less time in euglycemia than
subjects in nasulin group, the different was not statistically significant
* Says will not commence its planned phase 2b trial or other nasulin
development initiatives
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about CPEX Pharmaceuticals Inc click here:) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.